Chronic Lymphocytic Leukemia

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

By

A retrospective study sought to evaluate outcomes for patients with CLL who were treated with FCR, a highly effective treatment, and initially had refractory disease, experienced relapse early, or were unable to complete therapy due to toxicity.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

By

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

By

A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.

Venetoclax plus rituximab increases progression-free survival in relapsed chronic lymphocytic leukemia

1. Patients with relapsed or remitting chronic lymphocytic leukemia (CLL) treated with venetoclax-rituximab had a greater 2-year progression-free survival rate compared to bendamustine-rituximab treated patients. 2. Progression-free survival rates were greater for venetoclax-rituximab patients in almost all subgroup analysis, including patients with chromosome 17p deletion. Evidence Rating Level: 1 (Excellent) Study Rundown: Curative treatment of relapsed []

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

By

Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.

Monitoring Patients With Chronic Lymphocytic Leukemia  Treated With Venetoclax

Monitoring Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax

By

What are key monitoring guidelines for patients with CLL being treated with venetoclax?

2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL

2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL

By

Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

By

The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

By

Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.

Lenalidomide Maintenance Therapy Reduced Risk of Progression in CLL

Lenalidomide Maintenance Therapy Reduced Risk of Progression in CLL

Results of this double-blind, phase 3 study reports on impact of lenalidomide maintenance therapy on risk of disease progression in patients with CLL who did not achieve minimal residual disease state after first-line chemoimmunotherapy.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

By

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia

Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia

By

Case study demonstrates the effectiveness of long-term treatment with an oral nonpeptide receptor agonist in a 69-year-old male patient with CLL-associated ITP.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

By

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

What Is The Optimal Sequencing of Novel Agents for CLL?

What Is The Optimal Sequencing of Novel Agents for CLL?

By

Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.

Ruxolitinib May Improve Symptom Control in Patients With CLL

Ruxolitinib May Improve Symptom Control in Patients With CLL

By

In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

By

Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.

ROR1 Expression May Enhance Disease Progression in CLL

ROR1 Expression May Enhance Disease Progression in CLL

By

Expression of ROR1 could promote leukemia-cell activation and enhance disease progression in patients with chronic lymphocytic leukemia, according to a study.

5-parameter Prognostic Index Useful for Predicting TTFT, OS in CLL

5-parameter Prognostic Index Useful for Predicting TTFT, OS in CLL

By

In an observational study of an independent cohort of patients with Binet stage A CLL, researchers sought to validate the ability of the CLL International Prognostic Index to predict time to first treatment (TTFT) and overall survival in patients with early-stage disease.

Chronic Lymphocytic Leukemia (Fact Sheet)

Chronic Lymphocytic Leukemia (Fact Sheet)

This fact sheet reviews the incidence and survival statistics of chronic lymphocytic leukemia.

Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain

Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain

[ClinicoEconomics and Outcomes Research] This research examines the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of previously untreated chronic lymphocytic leukemia.

MRD Assessment Improves PFS Prediction in Patients With CLL

MRD Assessment Improves PFS Prediction in Patients With CLL

By

Assessment of minimal residual disease (MRD) improves the prediction of progression-free survival benefit in patients with CLL who achieve either a complete response or a partial response PR.

Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL

Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL

By

The US Food and Drug Administration has approved ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of relapsed chronic lymphocytic leukemia (CLL).

Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion

Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion

By

Treatment with ibrutinib is associated with a high overall response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 17p deletion.

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

By

Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

By

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Rituximab Maintenance Prolongs PFS in Patients With CLL

Rituximab Maintenance Prolongs PFS in Patients With CLL

By

New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

By

An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

By

The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.

Hair, Nail Abnormalities Common With Ibrutinib Therapy

Hair, Nail Abnormalities Common With Ibrutinib Therapy

By

Hair and nail abnormalities are commonly associated with the Bruton tyrosine kinase inhibitor ibrutinib.

Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and Metastasis

Immunotherapeutic Agent Blocks Protein-Protein Interaction That Supports Chronic Lymphocytic Leukemia Growth and Metastasis

By

Wnt5a protein acts on a pair of tumor-surface proteins to accelerate the proliferation and spread of CLL. These effects of Wnt5a were blocked by a humanized monoclonal antibody called cirmtuzumab, according to a recent study.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs